Skip to Main Content
Phase III

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

  • Study HIC#:2000036599
  • Last Updated:04/11/2024

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

  • GenderFemale only

Contact Us

For more information about this study, including how to volunteer, contact:

Lisa Baker

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact, or call +18779788343 for more information.

Trial Purpose and Description

This international, randomized, open-label, Phase 3 study will compare the investigational combination of avutometinib plus defactinib versus Investigator's Choice of Treatments (ICT) in patients with recurrent LGSOC who have progressed on a prior platinum-based therapy. Avutometinib and defactinib are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. The study will compare the progression-free survival (PFS) of the combination of avutometinib plus defactinib versus ICT. The study will also evaluate the effect of the combination on safety, overall survival, other efficacy endpoints, and health-related quality of life and disease related symptoms. The study is being conducted by gynecological cancer specialists. Patients who are eligible and agree to participate in this study will be treated with either a combination of avutometinib with defactinib, or with one of five standard of care NCCN and ESMO treatment recommendations for recurrent LGSOC, and then with subsequent follow up appointments. Patients who originally received one of the standard of care treatments who are determined to have progressive disease may be eligible to crossover to receive the investigational combination avutometinib plus defactinib.Avutometinib and defactinib are investigational drugs that have not been approved by the U.S. Food and Drug Administration (FDA)

Eligibility Criteria

Patients may be eligible for inclusion in the study if they meet the following criteria:

  1. Histologically proven LGSOC (ovarian, fallopian, peritoneal)
  2. Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease.
  3. Measurable disease according to RECIST v1.1.
  4. An Eastern Cooperative Group (ECOG) performance status ≤ 1.
  5. Adequate organ function
  6. Adequate recovery from toxicities related to prior treatments.
  7. For patients with reproductive potential, Agreement to use highly effective method of contraceptive.
  8. Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

  1. Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy.
  2. Co-existing high-grade ovarian cancer or another histology.
  3. Prior treatment with avutometinib, defactinib, or other FAK inhibitors.
  4. History of prior malignancy with recurrence <3 years from the time of enrollment.
  5. Major surgery within 4 weeks.
  6. Symptomatic brain metastases or spinal cord compression.
  7. An active skin disorder that has required systemic therapy within one year of signing informed consent.
  8. History of medically significant rhabdomyolysis.
  9. For subjects with prior MEK exposure, Grade 4 toxicity deemed related to the MEK inhibitor.
  10. Symptomatic bowel obstruction within 3 months.
  11. Concurrent ocular disorders.
  12. Concurrent heart disease or severe obstructive pulmonary disease.
  13. Subjects with the inability to swallow oral medications.
  14. Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy.

Principal Investigator


For more information about this study, including how to volunteer, contact: